Targeting amino acid metabolic reprogramming via l-type amino acid transporter 1 (Lat1) for endocrine-resistant breast cancer

Haruhiko Shindo, Narumi Harada-Shoji, Akiko Ebata, Miku Sato, Tomoyoshi Soga, Minoru Miyashita, Hiroshi Tada, Masaaki Kawai, Shinkichi Kosaka, Koji Onuki, Shin Usami, Shozo Furumoto, Shinichi Hayashi, Takaaki Abe, Takashi Suzuki, Takanori Ishida, Hironobu Sasano

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


The PI3K/Akt/mTOR pathway has been well known to interact with the estrogen receptor (ER)-pathway and to be also frequently upregulated in aromatase inhibitor (AI)-resistant breast cancer patients. Intracellular levels of free amino acids, especially leucine, regulate the mammalian target of rapamycin complex 1 (mTORC1) activation. L-type amino acid transporters such as LAT1 and LAT3 are associated with the uptake of essential amino acids. LAT1 expression could mediate leucine uptake, mTORC1 signaling, and cell proliferation. Therefore, in this study, we explored amino acid metabolism, including LAT1, in breast cancer and clarified the potential roles of LAT1 in the development of therapeutic resistance and the eventual clinical outcome of the patients. We evaluated LAT1 and LAT3 expression before and after neoadjuvant hormone therapy (NAH) and examined LAT1 function and expression in estrogen deprivation-resistant (EDR) breast carcinoma cell lines. Tumors tended to be in advanced stages in the cases whose LAT1 expression was high. LAT1 expression in the EDR cell lines was upregulated. JPH203, a selective LAT1 inhibitor, demonstrated inhibitory effects on cell proliferation in EDR cells. Hormone therapy changed the tumor microen-vironment and resulted in metabolic reprogramming through inducing LAT1 expression. LAT1 expression then mediated leucine uptake, enhanced mTORC1 signaling, and eventually resulted in AI resistance. Therefore, LAT1 could be the potential therapeutic target in AI-resistant breast cancer patients.

Original languageEnglish
Article number4375
Issue number17
Publication statusPublished - 2021 Sept 1


  • Amino acid metabolism
  • Breast cancer
  • Hormone therapy
  • JPH203
  • SLC43A1 (LAT3)
  • SLC7A5 (LAT1)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Targeting amino acid metabolic reprogramming via l-type amino acid transporter 1 (Lat1) for endocrine-resistant breast cancer'. Together they form a unique fingerprint.

Cite this